Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Michael L. Beshiri"'
Autor:
Fatima Karzai, David VanderWeele, Ravi A. Madan, Helen Owens, Lisa M. Cordes, Amy Hankin, Anna Couvillon, Erin Nichols, Marijo Bilusic, Michael L. Beshiri, Kathleen Kelly, Venkatesh Krishnasamy, Sunmin Lee, Min-Jung Lee, Akira Yuno, Jane B. Trepel, Maria J. Merino, Ryan Dittamore, Jennifer Marté, Renee N. Donahue, Jeffrey Schlom, Keith J. Killian, Paul S. Meltzer, Seth M. Steinberg, James L. Gulley, Jung-Min Lee, William L. Dahut
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-12 (2018)
Abstract Background Checkpoint inhibitors have not been effective for prostate cancer as single agents. Durvalumab is a human IgG1-K monoclonal antibody that targets programmed death ligand 1 and is approved by the U.S. Food and Drug Administration f
Externí odkaz:
https://doaj.org/article/0cf7309b04d14ab6b60eafc1dd43beb1
Autor:
Justin H. Hwang, Ji-Heui Seo, Michael L. Beshiri, Stephanie Wankowicz, David Liu, Alexander Cheung, Ji Li, Xintao Qiu, Andrew L. Hong, Ginevra Botta, Lior Golumb, Camden Richter, Jonathan So, Gabriel J. Sandoval, Andrew O. Giacomelli, Seav Huong Ly, Celine Han, Chao Dai, Hubert Pakula, Anjali Sheahan, Federica Piccioni, Ole Gjoerup, Massimo Loda, Adam G. Sowalsky, Leigh Ellis, Henry Long, David E. Root, Kathleen Kelly, Eliezer M. Van Allen, Matthew L. Freedman, Atish D. Choudhury, William C. Hahn
Publikováno v:
Cell Reports, Vol 29, Iss 8, Pp 2355-2370.e6 (2019)
Summary: Androgen-receptor (AR) inhibitors, including enzalutamide, are used for treatment of all metastatic castration-resistant prostate cancers (mCRPCs). However, some patients develop resistance or never respond. We find that the transcription fa
Externí odkaz:
https://doaj.org/article/40f707e6f0e3479da1c48a8eaa450461
Autor:
David J. VanderWeele, Kathleen Kelly, Brian Capaldo, Jose Antonio Rodriguez-Nieves, Supreet Agarwal, Michael L. Beshiri, Keith H. Jansson, Wardah Bajwa, Adlai R. Grayson, Aian Neil Alilin, Yen Thi Minh Nguyen, Berkley E. Gryder, Remi Adelaiye-Ogala
The PI3K–AKT pathway has pleiotropic effects and its inhibition has long been of interest in the management of prostate cancer, where a compensatory increase in PI3K signaling has been reported following androgen receptor (AR) blockade. Prostate ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a46cecee709ae33154b3f4813804f90
https://doi.org/10.1158/1535-7163.c.6542743
https://doi.org/10.1158/1535-7163.c.6542743
Autor:
David J. VanderWeele, Kathleen Kelly, Brian Capaldo, Jose Antonio Rodriguez-Nieves, Supreet Agarwal, Michael L. Beshiri, Keith H. Jansson, Wardah Bajwa, Adlai R. Grayson, Aian Neil Alilin, Yen Thi Minh Nguyen, Berkley E. Gryder, Remi Adelaiye-Ogala
Supplementary Figure 1. Assessment of ipatasertib as single agent across models representing hormone sensitive PCa in vitro. Supplementary Figure 2. Assessment of ipatasertib on GR expression. Supplementary Figure 3. Western blot indicating effects o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::638205aede72c51a0bd40ad2d6b64166
https://doi.org/10.1158/1535-7163.22520719
https://doi.org/10.1158/1535-7163.22520719
Autor:
Yves Pommier, Kathleen Kelly, Junko Murai, Moudjib Etemadi, Michael L. Beshiri, Shyam K. Sharan, Zoe Weaver Ohler, Melanie Gordon, Ludmila Szabova, Laetitia Marzi
CellMinerCDB snapshots (http://discover.nci.nih.gov/cellminercdb) demonstrating the correlations between the activity of the three clinical indenoisoquinolines and topotecan activity.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3611cadf995f520ad4c1fd6ede770871
https://doi.org/10.1158/1078-0432.22471661
https://doi.org/10.1158/1078-0432.22471661
Autor:
Yves Pommier, Kathleen Kelly, Junko Murai, Moudjib Etemadi, Michael L. Beshiri, Shyam K. Sharan, Zoe Weaver Ohler, Melanie Gordon, Ludmila Szabova, Laetitia Marzi
CellMinerCDB snapshots (http://discover.nci.nih.gov/cellminercdb) demonstrating the correlations between the activity of the three clinical indenoisoquinolines and SLFN11 expression in the NCI-60 (A-C) and in the GDSC (MGH-Sanger) panels of non-isoge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51aa820b6ddc6f741d53766919d8f8cb
https://doi.org/10.1158/1078-0432.22471664.v1
https://doi.org/10.1158/1078-0432.22471664.v1
Autor:
Yves Pommier, Kathleen Kelly, Junko Murai, Moudjib Etemadi, Michael L. Beshiri, Shyam K. Sharan, Zoe Weaver Ohler, Melanie Gordon, Ludmila Szabova, Laetitia Marzi
LMP400 activity values for all NCI-60 cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8c2156d72b9f22c89c4099fc876ef12
https://doi.org/10.1158/1078-0432.22471649.v1
https://doi.org/10.1158/1078-0432.22471649.v1
Autor:
Yves Pommier, Kathleen Kelly, Junko Murai, Moudjib Etemadi, Michael L. Beshiri, Shyam K. Sharan, Zoe Weaver Ohler, Melanie Gordon, Ludmila Szabova, Laetitia Marzi
LMP776 is synergistic with talazoparib in BRCA1-/- cells. Cell viability curves of talazoparib in DT40 WT (blue symbols and curves) and BRCA1-/- cells (red) with the indicated concentrations of LMP776. Open symbols and dashed lines correspond to tala
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18ad9ccbb8b853661e9f615bbbb6248e
https://doi.org/10.1158/1078-0432.22471658
https://doi.org/10.1158/1078-0432.22471658
Autor:
Kathleen Kelly, Eva Corey, William L. Dahut, Fatima H. Karzai, Aian Neil Alilin, JuanJuan Yin, Kerry M. McGowen, Qi Yang, Keith H. Jansson, Supreet Agarwal, Adam G. Sowalsky, Holly M. Nguyen, Crystal Tran, Caitlin M. Tice, Michael L. Beshiri
Tables of compounds, recombinant proteins, antibodies, and primers used
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b1955754f2f32f5c01080606f8dc1be
https://doi.org/10.1158/1078-0432.22469744
https://doi.org/10.1158/1078-0432.22469744
Autor:
Yves Pommier, Kathleen Kelly, Junko Murai, Moudjib Etemadi, Michael L. Beshiri, Shyam K. Sharan, Zoe Weaver Ohler, Melanie Gordon, Ludmila Szabova, Laetitia Marzi
Purpose:Irinotecan and topotecan are used to treat a variety of different cancers. However, they have limitations, including chemical instability and severe side effects. To overcome these limitations, we developed the clinical indenoisoquinolines: L
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d75a6b3f3bb6ff9de6341f4761433484
https://doi.org/10.1158/1078-0432.c.6527957
https://doi.org/10.1158/1078-0432.c.6527957